Long-Term Clinical Benefit Observed With KTE-X19 for Treatment of Relapsed/Refractory B-ALL

Retrieved on: 2021-06-05 14:26:15

Tags for this article:

Click the tags to see associated articles and topics

Long-Term Clinical Benefit Observed With KTE-X19 for Treatment of Relapsed/Refractory B-ALL. View article details on hiswai:

Excerpt

Heavily pretreated patients with relapsed/refractory B-ALL who received a single infusion of KTE-X19 experienced robust and durable responses.

Article found on: www.cancernetwork.com